3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria

A possible mechanism of AZT hepatotoxicity

Matthew D. Lynx, Alice T. Bentley, Edward E. McKee

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

3′-Azido-3′-deoxythymidine (AZT) is a staple of highly active antiretroviral therapy (HAART). Prior to HAART, long-term use of high-dosage AZT caused myopathy, cardiomyopathy, and hepatotoxicity, associated with mitochondrial DNA depletion. As a component of HARRT, AZT causes cytopenias and lipodystrophy. AZT-5′-triphosphate (AZTTP) is a known inhibitor of the mitochondrial polymerase γ and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart mitochondria, AZT phosphorylation beyond AZT-5′-monophosphate (AZTMP) was not detected. Rather, AZT was shown to be a more potent inhibitor of thymidine phosphorylation (50% inhibitory concentration (IC50) of 7.0 ± 1.0 μM) than AZTTP is of polymerase γ (IC50 of >100 μM), suggesting that depletion of mitochondrial stores of TTP may limit replication. This work has investigated whether an identical mechanism might account for the hepatotoxicity seen with long-term use of AZT. Isolated rat liver mitochondria were incubated with labeled thymidine or AZT, and the rate and extent of phosphorylation were determined by HPLC analysis of acid-soluble extracts of the incubated mitochondria. The results showed that in the phosphorylation of thymidine to TMP, liver mitochondria exhibit a higher Vmax and Km than heart mitochondria, but otherwise heart and liver mitochondria display similar kinetics. AZT is phosphorylated to AZTMP, but no further phosphorylated forms were detected. In addition, AZT inhibited the production of TTP, with an IC 50 of 14.4 ± 2.6 μM AZT. This is higher, but comparable to, the results seen in isolated rat heart mitochondria.

Original languageEnglish
Pages (from-to)1342-1348
Number of pages7
JournalBiochemical Pharmacology
Volume71
Issue number9
DOIs
StatePublished - Apr 28 2006

Fingerprint

Heart Mitochondria
Phosphorylation
Mitochondria
Zidovudine
Liver Mitochondrion
Liver
Thymidine
Rats
Inhibitory Concentration 50
Highly Active Antiretroviral Therapy
Mitochondrial DNA
Thymidine Monophosphate
Lipodystrophy
Muscular Diseases
Cardiomyopathies
High Pressure Liquid Chromatography
Acids
Kinetics
3'-azido-3'-deoxythymidine 5'-triphosphate
thymidine 5'-triphosphate

Keywords

  • AZT
  • Liver mitochondria
  • Mitochondrial toxicity
  • Reverse transcriptase inhibitors
  • Thymidine
  • Thymidine kinase 2

ASJC Scopus subject areas

  • Pharmacology

Cite this

3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria : A possible mechanism of AZT hepatotoxicity. / Lynx, Matthew D.; Bentley, Alice T.; McKee, Edward E.

In: Biochemical Pharmacology, Vol. 71, No. 9, 28.04.2006, p. 1342-1348.

Research output: Contribution to journalArticle

@article{5c7c011bf5a54365aee665f79e46bc2e,
title = "3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria: A possible mechanism of AZT hepatotoxicity",
abstract = "3′-Azido-3′-deoxythymidine (AZT) is a staple of highly active antiretroviral therapy (HAART). Prior to HAART, long-term use of high-dosage AZT caused myopathy, cardiomyopathy, and hepatotoxicity, associated with mitochondrial DNA depletion. As a component of HARRT, AZT causes cytopenias and lipodystrophy. AZT-5′-triphosphate (AZTTP) is a known inhibitor of the mitochondrial polymerase γ and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart mitochondria, AZT phosphorylation beyond AZT-5′-monophosphate (AZTMP) was not detected. Rather, AZT was shown to be a more potent inhibitor of thymidine phosphorylation (50{\%} inhibitory concentration (IC50) of 7.0 ± 1.0 μM) than AZTTP is of polymerase γ (IC50 of >100 μM), suggesting that depletion of mitochondrial stores of TTP may limit replication. This work has investigated whether an identical mechanism might account for the hepatotoxicity seen with long-term use of AZT. Isolated rat liver mitochondria were incubated with labeled thymidine or AZT, and the rate and extent of phosphorylation were determined by HPLC analysis of acid-soluble extracts of the incubated mitochondria. The results showed that in the phosphorylation of thymidine to TMP, liver mitochondria exhibit a higher Vmax and Km than heart mitochondria, but otherwise heart and liver mitochondria display similar kinetics. AZT is phosphorylated to AZTMP, but no further phosphorylated forms were detected. In addition, AZT inhibited the production of TTP, with an IC 50 of 14.4 ± 2.6 μM AZT. This is higher, but comparable to, the results seen in isolated rat heart mitochondria.",
keywords = "AZT, Liver mitochondria, Mitochondrial toxicity, Reverse transcriptase inhibitors, Thymidine, Thymidine kinase 2",
author = "Lynx, {Matthew D.} and Bentley, {Alice T.} and McKee, {Edward E.}",
year = "2006",
month = "4",
day = "28",
doi = "10.1016/j.bcp.2006.01.003",
language = "English",
volume = "71",
pages = "1342--1348",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - 3′-Azido-3′-deoxythymidine (AZT) inhibits thymidine phosphorylation in isolated rat liver mitochondria

T2 - A possible mechanism of AZT hepatotoxicity

AU - Lynx, Matthew D.

AU - Bentley, Alice T.

AU - McKee, Edward E.

PY - 2006/4/28

Y1 - 2006/4/28

N2 - 3′-Azido-3′-deoxythymidine (AZT) is a staple of highly active antiretroviral therapy (HAART). Prior to HAART, long-term use of high-dosage AZT caused myopathy, cardiomyopathy, and hepatotoxicity, associated with mitochondrial DNA depletion. As a component of HARRT, AZT causes cytopenias and lipodystrophy. AZT-5′-triphosphate (AZTTP) is a known inhibitor of the mitochondrial polymerase γ and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart mitochondria, AZT phosphorylation beyond AZT-5′-monophosphate (AZTMP) was not detected. Rather, AZT was shown to be a more potent inhibitor of thymidine phosphorylation (50% inhibitory concentration (IC50) of 7.0 ± 1.0 μM) than AZTTP is of polymerase γ (IC50 of >100 μM), suggesting that depletion of mitochondrial stores of TTP may limit replication. This work has investigated whether an identical mechanism might account for the hepatotoxicity seen with long-term use of AZT. Isolated rat liver mitochondria were incubated with labeled thymidine or AZT, and the rate and extent of phosphorylation were determined by HPLC analysis of acid-soluble extracts of the incubated mitochondria. The results showed that in the phosphorylation of thymidine to TMP, liver mitochondria exhibit a higher Vmax and Km than heart mitochondria, but otherwise heart and liver mitochondria display similar kinetics. AZT is phosphorylated to AZTMP, but no further phosphorylated forms were detected. In addition, AZT inhibited the production of TTP, with an IC 50 of 14.4 ± 2.6 μM AZT. This is higher, but comparable to, the results seen in isolated rat heart mitochondria.

AB - 3′-Azido-3′-deoxythymidine (AZT) is a staple of highly active antiretroviral therapy (HAART). Prior to HAART, long-term use of high-dosage AZT caused myopathy, cardiomyopathy, and hepatotoxicity, associated with mitochondrial DNA depletion. As a component of HARRT, AZT causes cytopenias and lipodystrophy. AZT-5′-triphosphate (AZTTP) is a known inhibitor of the mitochondrial polymerase γ and has been targeted as the source of the mitochondrial DNA depletion. However, in previous work from this laboratory with isolated rat heart mitochondria, AZT phosphorylation beyond AZT-5′-monophosphate (AZTMP) was not detected. Rather, AZT was shown to be a more potent inhibitor of thymidine phosphorylation (50% inhibitory concentration (IC50) of 7.0 ± 1.0 μM) than AZTTP is of polymerase γ (IC50 of >100 μM), suggesting that depletion of mitochondrial stores of TTP may limit replication. This work has investigated whether an identical mechanism might account for the hepatotoxicity seen with long-term use of AZT. Isolated rat liver mitochondria were incubated with labeled thymidine or AZT, and the rate and extent of phosphorylation were determined by HPLC analysis of acid-soluble extracts of the incubated mitochondria. The results showed that in the phosphorylation of thymidine to TMP, liver mitochondria exhibit a higher Vmax and Km than heart mitochondria, but otherwise heart and liver mitochondria display similar kinetics. AZT is phosphorylated to AZTMP, but no further phosphorylated forms were detected. In addition, AZT inhibited the production of TTP, with an IC 50 of 14.4 ± 2.6 μM AZT. This is higher, but comparable to, the results seen in isolated rat heart mitochondria.

KW - AZT

KW - Liver mitochondria

KW - Mitochondrial toxicity

KW - Reverse transcriptase inhibitors

KW - Thymidine

KW - Thymidine kinase 2

UR - http://www.scopus.com/inward/record.url?scp=33645124958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645124958&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2006.01.003

DO - 10.1016/j.bcp.2006.01.003

M3 - Article

VL - 71

SP - 1342

EP - 1348

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 9

ER -